French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still lo
- PDF / 1,329,430 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 24 Downloads / 159 Views
RESEARCH ARTICLE
Open Access
French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long Cécile Brouard1* , Josiane Pillonel1, Marjorie Boussac1,2, Victor de Lédinghen3,4, Antoine Rachas2, Christine Silvain5, Nathalie Lydié1, Stéphane Chevaliez6,7, Corinne Pioche1, Julien Durand1, Florence Lot1 and Elisabeth Delarocque-Astagneau8,9
Abstract Background: Hepatitis C virus (HCV) elimination by 2030, as targeted by the World Health Organization (WHO), requires that 90% of people with chronic infection be diagnosed and 80% treated. We estimated the cascade of care (CoC) for chronic HCV infection in mainland France in 2011 and 2016, before and after the introduction of direct-acting antivirals (DAAs). Methods: The numbers of people (1) with chronic HCV infection, (2) aware of their infection, (3) receiving care for HCV and (4) on antiviral treatment, were estimated for 2011 and 2016. Estimates for 1) and 2) were based on modelling studies for 2011 and on a virological sub-study nested in a national cross-sectional survey among the general population for 2016. Estimates for 3) and 4) were made using the National Health Data System. Results: Between 2011 and 2016, the number of people with chronic HCV infection decreased by 31%, from 192,700 (95% Credibility interval: 150,900-246,100) to 133,500 (95% Confidence interval: 56,900-312,600). The proportion of people aware of their infection rose from 57.7 to 80.6%. The number of people receiving care for HCV increased by 22.5% (representing 25.7% of those infected in 2016), while the number of people on treatment increased by 24.6% (representing 12.1% of those infected in 2016). Conclusions: This study suggests that DAAs substantially impact CoC. However, access to care and treatment for infected people remained insufficient in 2016. Updating CoC estimates will help to assess the impact of new measures implemented since 2016 as part of the goal to eliminate HCV. Keywords: Hepatitis C, Cascade of care, Elimination, Direct-acting antivirals, Prevalence, Diagnosis, Management, Treatment, France
* Correspondence: [email protected] 1 Santé publique France, the National Public Health Agency, Saint-Maurice, France Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will
Data Loading...
